ArticlePharmaceuticals (Basel, Switzerland)2012
The Potential Therapeutic Efficacy of Lactobacillus GG in Children with Food Allergies.
Article in Pharmaceuticals (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Christensenella minuta protects and restores intestinal barrier in a colitis mouse model by regulating inflammation.NPJ biofilms and microbiomes · 2024Article
- A Review on Maternal and Infant Microbiota and Their Implications for the Prevention and Treatment of Allergic Diseases.Nutrients · 2023Review
- Do advanced glycation end products contribute to food allergy?Frontiers in allergy · 2023Review
- Effects of early energy intake on neonatal cerebral growth of preterm newborn: an observational study.Scientific reports · 2021Observational
- Morbidity associated with patent ductus arteriosus in preterm newborns: a retrospective case-control study.Italian journal of pediatrics · 2021Article
- Immunonutrition for Pediatric Patients With Cow's Milk Allergy: How Early Interventions Could Impact Long-Term Outcomes.Frontiers in allergy · 2021Review
- Relative cost-effectiveness of using an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow's milk allergy in Poland.ClinicoEconomics and outcomes research : CEOR · 2016Article
- [In time: misuse and overuse of amino acid formulas in cow milk allergy].Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2015Article
- Relative cost-effectiveness of using an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow's milk allergy in Spain.ClinicoEconomics and outcomes research : CEOR · 2015Article
- Gut microbiota as potential therapeutic target for the treatment of cow's milk allergy.Nutrients · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Food allergy (FA) continues to be a growing health concern for infants living in Western countries. The long-term prognosis for the majority of affected infants is good, with 80-90% naturally acquiring tolerance by the age of five years. However, recent studies suggest that the natural history of FA is changing, with an increasing persistence until later ages. The pathogenesis of FA as well as oral tolerance is complex and not completely known, although numerous studies implicate gut-associated immunity and enteric microflora, and it has been suggested that an altered composition of intestinal microflora results in an unbalanced local and systemic immune response to food allergens. In addition, there are qualitative and quantitative differences in the composition of gut microbiota between patients affected by FA and healthy infants. These findings prompted the concept that specific beneficial bacteria from the human intestinal microflora, designated probiotics, could restore intestinal homeostasis and prevent or alleviate allergy, at least in part by interacting with the intestinal immune cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.